Mandate

Vinge acts for Medivir in connection with public offer

April 13, 2011

Vinge acts for Medivir in connection with the public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm) has announced a public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm). Vinge acts for Medivir.

Vinge’s team is headed by capital markets and public M&A partner Erik Sjöman and includes, among others, Christian Lindhé, Emil Hedberg, Jakob Warren and Markus Larsson. Göran Nyström (public M&A), Kristian Hugmark and Hanna Danwall (competition law) and Mattias Schömer and Maria Doeser (tax) are also on the team.

Related

Vinge advises Symrise on its public offer for Probi

Symrise AG has announced a public cash offer to the shareholders of Probi AB (publ) (“Probi”). The offer values Probi at approximately SEK 3,988 million. The shares in Probi are traded on Nasdaq Stockholm, Mid Cap.
November 20, 2024

Vinge advises Oxx in conjunction with an investment in Kodiak Hub

Kodiak Hub, a Swedish software as a service (SaaS) company, which offers its customers an AI-based software platform, has performed a capital procurement of EUR 6 million. The venture capital fund Oxx, which invests in SaaS companies, is the largest investor.
November 20, 2024

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.
November 19, 2024